Scholar Rock Missed Consensus Estimates

Scholar Rock (SRRK) reported a loss of $0.67 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.63 per share on revenue of $33.70 million. The company missed consensus estimates by 6.35%.

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.